Quick Takes
Page Tools
• A report in the May 7, 2010, Morbidity and Mortality Weekly Report (MMWR) presents new recommendations regarding use of the combination measles, mumps, rubella, and varicella vaccine.
The recommendations were adopted in June 2009 by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. The report is available at http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5903a1.htm.
• When the FDA Drug Safety and Risk Management Committee meets on September 14, 2010, its members will discuss the abuse potential of dextromethorphan and the public health benefits and risks of dextromethorphan use as a cough suppressant. The Drug Enforcement Administration asked the Department of Health and Human Services for a scientific and medical evaluation and scheduling recommendation for dextromethorphan in response to the increased incidence of abuse, especially among adolescents.
• Based on careful evaluation of a variety of scientific information, the FDA has determined that it is appropriate for clinicians and health care professionals to resume the use of Rotarix and to continue the use of RotaTeq rotavirus vaccines. The FDA is working with each of the manufacturers to update product labeling to include information about the presence of porcine circovirus type 1 (PCV1) in Rotarix and DNA from both PCV1 and porcine circovirus type 1 (PCV2) in RotaTeq.